Paradigm Capital Management Inc. NY Reduces Stock Holdings in OrthoPediatrics Corp. (NASDAQ:KIDS)

Paradigm Capital Management Inc. NY lessened its position in shares of OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 93.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 10,000 shares of the company's stock after selling 133,400 shares during the quarter. Paradigm Capital Management Inc. NY's holdings in OrthoPediatrics were worth $232,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. R Squared Ltd purchased a new stake in shares of OrthoPediatrics in the fourth quarter valued at about $48,000. Rhumbline Advisers lifted its position in shares of OrthoPediatrics by 4.1% in the fourth quarter. Rhumbline Advisers now owns 26,411 shares of the company's stock valued at $612,000 after acquiring an additional 1,042 shares in the last quarter. AlphaCentric Advisors LLC acquired a new stake in shares of OrthoPediatrics during the fourth quarter valued at $171,000. Bank of New York Mellon Corp increased its position in OrthoPediatrics by 3.8% during the 4th quarter. Bank of New York Mellon Corp now owns 57,710 shares of the company's stock worth $1,338,000 after purchasing an additional 2,099 shares in the last quarter. Finally, Mutual of America Capital Management LLC increased its position in OrthoPediatrics by 57.1% during the 4th quarter. Mutual of America Capital Management LLC now owns 169,021 shares of the company's stock worth $3,918,000 after purchasing an additional 61,412 shares in the last quarter. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at OrthoPediatrics

In other news, insider Gregory A. Odle sold 5,359 shares of the business's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $133,224.74. Following the completion of the sale, the insider now owns 148,788 shares of the company's stock, valued at approximately $3,698,869.68. The trade was a 3.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO David R. Bailey sold 6,620 shares of the company's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $164,573.20. Following the completion of the sale, the chief executive officer now owns 319,155 shares in the company, valued at approximately $7,934,193.30. This trade represents a 2.03% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 23,732 shares of company stock valued at $589,978 over the last ninety days. Corporate insiders own 32.70% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Truist Financial lowered their price target on shares of OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating for the company in a report on Friday, April 11th. Lake Street Capital began coverage on OrthoPediatrics in a report on Monday, April 7th. They set a "buy" rating and a $37.00 price objective on the stock. Needham & Company LLC reiterated a "buy" rating and set a $42.00 target price on shares of OrthoPediatrics in a research report on Thursday, May 8th. Stifel Nicolaus cut their price objective on shares of OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, March 5th. Finally, Piper Sandler cut their price target on shares of OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, OrthoPediatrics currently has a consensus rating of "Moderate Buy" and an average target price of $35.83.

OrthoPediatrics Price Performance

KIDS opened at $22.95 on Tuesday. OrthoPediatrics Corp. has a twelve month low of $20.25 and a twelve month high of $35.99. The firm has a market cap of $557.39 million, a price-to-earnings ratio of -18.66 and a beta of 1.09. The company has a current ratio of 7.17, a quick ratio of 3.68 and a debt-to-equity ratio of 0.19. The company has a fifty day simple moving average of $22.80 and a 200 day simple moving average of $23.92.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.13). OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The business had revenue of $52.41 million for the quarter, compared to analysts' expectations of $51.68 million. Equities research analysts expect that OrthoPediatrics Corp. will post -0.93 EPS for the current fiscal year.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.

Want to see what other hedge funds are holding KIDS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.